The GP is focused on textile-based media for severe burn injuries, developed by novel electrospinning technology, which promotes cell growth of the skin
This GP involves electrospinning technology, bio-compatible polymers, cell culture and in-vitro/animal in-vivo modellization and validation. It starts with the development of bio-compatible poly (D,L-lactide-co-glycolide) (DLPLG) nanofiber webs through electrospinning technology (monoaxial). This nanostructured textile biomaterial is used as a scaffold for cells in order to promote their growth. Nanofibers are able to integrate into fibrin matrix and they are permeable to nutrients and cells and, in addition, these new dermal equivalents with nanofibers are optimal for clinical handling.
The nanofiber scaffolds are used, then, for cell culture and growing of dermal cells (fibroblasts and autologous keratinocytes) is tested using in-vitro and in-vivo animal models. The biological characterization of these nanotextile-based biomaterials show that new dermal equivalents have angiogenic capacity (it promotes formation of new blood vessels) and they improve scar quality, less tension, smooth surface of the ‘new’ skin.
These bio-compatible nanotextiles are currently being produced by AITEX but the final goal is the production at industrial scale by the company manufacturing electrospinning technology or even by textile companies specialized in nonwovens and/or medical products.
Paying attention to the technology (mono- or multi-axial electrospinning) an estimation of funding for set up and run this equipment could be: 80k - 120k €.
Human resources (only for research and development of nanotextiles by electrospinning): textile engineers, chemical engineers.
Evidence of success
- Successful results in terms of development of nanofibers and webs. Promising nanostructures and nanofiber webs developed with biopolymers have been developed. Possibilities to enhance functionalities of these nanofibers doping them with drugs or growing factors will be considered.
- Results achieved in pre-clinical trials show that implantation of these textile-based biomaterials promotes cell growth, formation of new blood vessels and improves ‘quality’ of the regenerated skin structure.
Potential for learning or transfer
•Electrospinning is a mature technology and some EU producers of end-products and machinery can be easily found.
•Intensive collaboration between partners with different profiles is required.
•Pay attention to legislation.
•Specialization of technicians driving electrospinning devices is required. Increasing of knowledge of technicians.
•Funding required for implementation, size of the machinery and auxiliary installation devices are not so high.
•Specialization and re-conversion of traditional textile companies that are currently producing sanitary goods, nonwovens or medical textiles
•Final benefits after validation at clinical stage will be transferred to people requiring regenerative medicine or skin dressing.
•Possibilities to launch R&D and cooperation projects at national/EU level.